UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 861

Sortiert nach

α-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice

Nature communications, 2023-10, Vol.14 (1), p.6892-6892, Article 6892

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II clinical trial of phlebotomy for non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.720-729

2013

Link zum Volltext

Verfügbarkeit prüfen

Insulator visual non-conformity detection in overhead power distribution lines using deep learning

Computers & electrical engineering, 2019-09, Vol.78, p.343-355

2019

Link zum Volltext

Verfügbarkeit prüfen

Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro

Acta neuropathologica communications, 2021-11, Vol.9 (1), p.188-188, Article 188

2021

Link zum Volltext

Verfügbarkeit prüfen

Theories of the Stranger: Debates on Cosmopolitanism, Identity and Cross-Cultural Encounters

Marotta, Vince

1, 2017

Link zum Volltext

Verfügbarkeit prüfen

N-Terminal Protein Modification Using Simple Aminoacyl Transferase Substrates

Journal of the American Chemical Society, 2011-09, Vol.133 (38), p.15139-15147

2011

Link zum Volltext

Verfügbarkeit prüfen

O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease

Nature chemistry, 2015-11, Vol.7 (11), p.913

2015

Link zum Volltext

Verfügbarkeit prüfen

Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology

Current opinion in neurobiology, 2022-02, Vol.72, p.171-177

2022

Link zum Volltext

Verfügbarkeit prüfen

Hepatocellular Carcinoma Response to Local Regional Therapy; Correlations between Pre-Liver Transplants Imaging and Explant Pathology

Journal of hepatology, 2016, Vol.64 (2), p.S333-S333

2016

Link zum Volltext

Verfügbarkeit prüfen

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

Journal of hepatology, 2012-04, Vol.56, p.S6-S7

2012

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of fat-soluble vitamin (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation

Acta gastro-enterologica belgica, 2017-04, Vol.80 (2), p.237-241

2017

Link zum Volltext

Verfügbarkeit prüfen

Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications

Biomolecules (Basel, Switzerland), 2015-06, Vol.5 (3), p.1210-1227

2015

Link zum Volltext

Verfügbarkeit prüfen

Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis

Hepatology (Baltimore, Md.), 1999-11, Vol.30 (5), p.1121-1127

1999

Link zum Volltext

Verfügbarkeit prüfen

Recurrence of primary sclerosing cholangitis following liver transplantation

Hepatology (Baltimore, Md.), 1999-04, Vol.29 (4), p.1050-1056

1999

Link zum Volltext

Verfügbarkeit prüfen

The New Chemical Reporter 6‑Alkynyl-6-deoxy-GlcNAc Reveals O‑GlcNAc Modification of the Apoptotic Caspases That Can Block the Cleavage/Activation of Caspase‑8

Journal of the American Chemical Society, 2017-06, Vol.139 (23), p.7872-7885

2017

Link zum Volltext

Verfügbarkeit prüfen

Semisynthetic, Site-Specific Ubiquitin Modification of α-Synuclein Reveals Differential Effects on Aggregation

Journal of the American Chemical Society, 2012-03, Vol.134 (12), p.5468-5471

2012

Link zum Volltext

Verfügbarkeit prüfen

Should a Lower Quality Organ Go to the Least Sick Patient? Model for End-Stage Liver Disease Score and Donor Risk Index as Predictors of Early Allograft Dysfunction

Transplantation proceedings, 2012-06, Vol.44 (5), p.1303-1306

2012

Link zum Volltext

Verfügbarkeit prüfen

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

European journal of clinical microbiology & infectious diseases, 2016-04, Vol.35 (4), p.597-609

2016

Link zum Volltext

Verfügbarkeit prüfen

O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein

Bioorganic & medicinal chemistry, 2017-09, Vol.25 (18), p.4977-4982

2017

Link zum Volltext

Verfügbarkeit prüfen

Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks is Effective and Safe in Treatment-Naïve Genotype-3 Hepatitis C-Infected Patients in Canada

Journal of hepatology, 2016, Vol.64 (2), p.S781-S781

2016

Link zum Volltext

Verfügbarkeit prüfen

O-GlcNAc Modification Prevents Peptide-Dependent Acceleration of α-Synuclein Aggregation

Chembiochem : a European journal of chemical biology, 2012-12, Vol.13 (18), p.2665-2670

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Genetic Changes Associated With Colorectal Carcinogenesis Are Not Prognostic for Tumor Regression Following Preoperative Chemoradiation of Rectal Carcinoma

International journal of radiation oncology, biology, physics, 2009-06, Vol.74 (2), p.472-476

2009

Link zum Volltext

Verfügbarkeit prüfen

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2011-03, Vol.364 (13), p.1207-1217

2011

Link zum Volltext

Verfügbarkeit prüfen

Sporadic desmoid tumor in an Ashkenazi patient homozygous for the APCI1307K gene mutation

Acta oncologica, 2008, Vol.47 (6), p.1158-1161

2008

Link zum Volltext

Verfügbarkeit prüfen

GNAS gene mutation may be present only transiently during colorectal tumorigenesis

International journal of molecular epidemiology and genetics, 2016-01, Vol.7 (1), p.24-31

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 861

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(734)
Mit Volltextzugriff
(730)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

α-Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice

Phase II clinical trial of phlebotomy for non‐alcoholic fatty liver disease

Insulator visual non-conformity detection in overhead power distribution lines using deep learning

Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro

Theories of the Stranger: Debates on Cosmopolitanism, Identity and Cross-Cultural Encounters

N-Terminal Protein Modification Using Simple Aminoacyl Transferase Substrates

O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease

Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology

Hepatocellular Carcinoma Response to Local Regional Therapy; Correlations between Pre-Liver Transplants Imaging and Explant Pathology

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

Prevalence of fat-soluble vitamin (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation

Synthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational Modifications

Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis

Recurrence of primary sclerosing cholangitis following liver transplantation

The New Chemical Reporter 6‑Alkynyl-6-deoxy-GlcNAc Reveals O‑GlcNAc Modification of the Apoptotic Caspases That Can Block the Cleavage/Activation of Caspase‑8

Semisynthetic, Site-Specific Ubiquitin Modification of α-Synuclein Reveals Differential Effects on Aggregation

Should a Lower Quality Organ Go to the Least Sick Patient? Model for End-Stage Liver Disease Score and Donor Risk Index as Predictors of Early Allograft Dysfunction

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies

O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein

Ledipasvir/Sofosbuvir with Ribavirin for 12 Weeks is Effective and Safe in Treatment-Naïve Genotype-3 Hepatitis C-Infected Patients in Canada

O-GlcNAc Modification Prevents Peptide-Dependent Acceleration of α-Synuclein Aggregation

Molecular Genetic Changes Associated With Colorectal Carcinogenesis Are Not Prognostic for Tumor Regression Following Preoperative Chemoradiation of Rectal Carcinoma

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Sporadic desmoid tumor in an Ashkenazi patient homozygous for the APCI1307K gene mutation

GNAS gene mutation may be present only transiently during colorectal tumorigenesis

Suchergebnisse filtern